DNA Script Presents Data at AGBT Confirming Functional Performance of the Company’s Enzymatic Synthesis (EDS) Technology

DNA Script, a leading pioneer in enabling DNA on demand, shared data at this year’sĀ Advances in Genome Biology and Technology (AGBT) General MeetingĀ that demonstrate the comparable performance of the company’s enzymatically synthesized oligos to traditional chemically synthesized DNA in their quest to reliably support genomics and life science applications. The research, in collaboration withĀ The Jackson LaboratoryĀ for Genomic Medicine and scientists fromĀ Mexico’sĀ Zacatecas State Health Services and the Autonomous University ofĀ Zacatecas, verified that primers developed for the detection and characterization of the SARS-CoV-2 virus, synthesized using DNA Script’s EDS technology, performed comparably to primers obtained from commercial suppliers, with both RNA controls and clinical samples. A poster of the results is available for viewing on the 2021 AGBT General Meeting website, and authors will be available for discussion during the virtual poster sessions today fromĀ 3:45-5:45 p.m. ESTĀ and tomorrow fromĀ 3:30-5:30 p.m. EST.